verbatim): The discovery of doxorubicin (Dox; Adriamycin) an antitumor antibiotic 40 years ago lead to a major step in the fight against cancer. The agent was found to be effective for the treatment especially of breast cancer and leukemia and remains a major component of the therapeutic armamentarium. Unfortunately, its clinical use is limited by life threatening dose-dependent cardiac side effects that lead to degenerative cardiomyopathy and congestive heart failure. The overall aim of this proposal is to elucidate the molecular genetic mechanisms of Dox cardiotoxicity. Our studies have demonstrated that Dox selectively dysregulates the expression of cardiac-specific or cardiac-restricted genes by depleting the levels of tissue specific transcription factors and co-factors. We will investigate the central roles of MEF2C:p300 interactions and MEF2C acetylation by p300 in cardiac specific gene expression and the response to Dox. Because Dox depletes p300 protein we will study whether Dox induces selective protein degradation of p300. Since P300 and El 2 can rescue the inhibition by Dox of transcription from MEF2C and E-box dependent promoters, respectively. We will deliver both p300 and El 2 to cardiomyocytes and to rat myocardium using newly developed lentiviral vectors. Finally we will investigate the function of the Cardiac Adriamycin Responsive Protein (CARP) that inhibits cell proliferation and may be the first member of the Ink4 family of cyclin dependent kinase inhibitors described in heart. These studies will help define the mechanisms of a serious cardiac side effect of a widely used cancer therapy and potentially lead to protective approaches.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
3R01HL052771-06S1
Application #
6355953
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Program Officer
Johnson, George S
Project Start
1995-05-01
Project End
2004-04-30
Budget Start
2000-07-01
Budget End
2001-04-30
Support Year
6
Fiscal Year
2000
Total Cost
$54,354
Indirect Cost
Name
University of Southern California
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Awad, Salma; Kunhi, Muhammad; Little, Gillian H et al. (2013) Nuclear CaMKII enhances histone H3 phosphorylation and remodels chromatin during cardiac hypertrophy. Nucleic Acids Res 41:7656-72
Little, Gillian H; Bai, Yan; Williams, Tyisha et al. (2007) Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells. J Biol Chem 282:7219-31
Kong, Kimi Y; Kedes, Larry (2006) Leucine 135 of tropomodulin-1 regulates its association with tropomyosin, its cellular localization, and the integrity of sarcomeres. J Biol Chem 281:9589-99
Dow, Joan; Simkhovich, Boris Z; Kedes, Larry et al. (2005) Washout of transplanted cells from the heart: a potential new hurdle for cell transplantation therapy. Cardiovasc Res 67:301-7
Simkhovich, Boris Z; Marjoram, Paul; Poizat, Coralie et al. (2003) Age-related changes of cardiac gene expression following myocardial ischemia/reperfusion. Arch Biochem Biophys 420:268-78
Puri, P L; Sartorelli, V; Yang, X J et al. (1997) Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1:35-45